Antibody Drug Conjugate Composed Of A Humanized Monoclonal Antibody Targeting Cldn18.2 And Linker-Payload Mc-Vc-Pab-Mmae
Cancer
Explore 1,380 assets in Cancer →Floatz Rating
CCC55/100
Confidence
Indicative
Sponsor
LaNova Australia Pty Limited
Modality
antibody_drug_conjugate
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05188664CT.gov Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT05001516CT.gov Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors | — | Completed | — | — | — |
NCT05161390CT.gov Study of LM-302 in Patients With Advance Solid Tumors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Antibody Drug Conjugate Composed Of A Humanized Monoclonal Antibody Targeting Cldn18.2 And Linker-Payload Mc-Vc-Pab-Mmae (this asset) | LaNova Australia Pty Limited | P1/2 | CCC · 55 |
| Nabiximols | Jazz Pharmaceuticals | P3 | BBB |
| Pyridoxol | M.D. Anderson Cancer Center | P4 | BB |
| Rivoceranib | Jiangsu HengRui Medicine Co., Ltd. | P4 | BB |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BB |
| Propofol | Hong Kong Children's Hospital | P4 | BB |
| Epirubicin | Zhejiang Provincial People's Hospital | P3 | BB |
| Atorvastatin | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | P2/3 | BB |
| Anamorelin | Helsinn Healthcare SA | P3 | BB |
+42 more in the Cancer cohort
Other indications for Antibody Drug Conjugate Composed Of A Humanized Monoclonal Antibody Targeting Cldn18.2 And Linker-Payload Mc-Vc-Pab-Mmae
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chemotherapy-Induced Toxicity | — | P2 | CCC · 53 |
| Pancreatic Neoplasm | — | P2 | CC · 46 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Antibody Drug Conjugate Composed Of A Humanized Monoclonal Antibody Targeting Cldn18.2 And Linker-Payload Mc-Vc-Pab-Mmae in Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/antibody-drug-conjugate-composed-of-a-humanized-monoclonal-antibody-targeting-cldn182-and-linker-payload-mc-vc-pab-mmae-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →